Page last updated: 2024-11-10

ketazocine

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

ketazocine: RN given refers to parent cpd(2S-(2alpha,6alpha,11S*))-isomer [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID3054741
CHEMBL ID2107292
SCHEMBL ID121212
MeSH IDM0059395

Synonyms (24)

Synonym
36292-69-0
ketazocine
win-34276
bdbm50027366
3-(cyclopropylmethyl)-3,4,5,6-tetrahydro-8-hydroxy-6,11-dimethyl-2,6-methano-3-benzazocin-1(2h)-one
CHEMBL2107292
(2r*,6s*,11s*)-3-(cyclopropylmethyl)-3,4,5,6-tetrahydro-8-hydroxy-6,11-dimethyl-2,6-methano-3-benzazocin-1(2h)-one
win 34,276
ketazocine [usan:inn]
6io4ig518s ,
ketazocina
2,6-methano-3-benzazocin-1(2h)-one, 3-(cyclopropylmethyl)-3,4,5,6-tetrahydro-8-hydroxy-6,11-dimethyl-, (2alpha,6alpha,11s*)-
ketazocinum [inn-latin]
ketazocina [inn-spanish]
ketazocinum
unii-6io4ig518s
ketazocine [inn]
2,6-methano-3-benzazocin-1(2h)-one, 3-(cyclopropylmethyl)-3,4,5,6-tetrahydro-8-hydroxy-6,11-dimethyl-, (2.alpha.,6.alpha.,11s*)-
ketazocine [usan]
SCHEMBL121212
AC-24848
Q6395335
(1r,9s,13r)-10-(cyclopropylmethyl)-4-hydroxy-1,13-dimethyl-10-azatricyclo[7.3.1.02,7]trideca-2(7),3,5-trien-8-one
AKOS040746949

Research Excerpts

Dosage Studied

ExcerptRelevanceReference
" Flumazenil (Ro 15-1788) administration caused a parallel shift to the right of the dose-response curve for midazolam spinal analgesia."( On the mechanism by which midazolam causes spinally mediated analgesia.
Edwards, M; Gent, JP; Goodchild, CS; Serrao, JM, 1990
)
0.28
" But a number of kappa agonists, including bremazocine, tifluadom, ethylketocyclazocine, ketocyclazocine, U-50,488 and Win 42,610 all depressed contractions, producing parallel dose-response curves."( Profile of activity of kappa receptor agonists in the rabbit vas deferens.
Hayes, A; Kelly, A, 1985
)
0.27
"Tolerance to the behavioral effects of selected opiate compounds (cyclazocine, ketocyclazocine, naloxone and the stereoisomers of N-allylnormetazocine) and phencyclidine was evaluated using cumulative dosing procedures in rhesus monkeys responding under a fixed-ratio (FR) schedule of food presentation."( Behavioral effects of selected opiates and phencyclidine in the nondependent and cyclazocine-dependent rhesus monkey.
Bergman, J; Hassoun, J; Schuster, CR, 1985
)
0.27
" Although the group X dosage interaction was not significant, an internally consistent tendency effect of naloxone among the different treatment groups was observed."( The effect of ovariectomy, estradiol and progesterone on opioid modulation of feeding.
Gosnell, BA; Grace, M; Kneip, J; Levine, AS; Morley, JE, 1984
)
0.27
" Ketocyclazocine dose-response functions were determined for each monkey under their original training conditions and then the conditions were reversed and dose-response functions were re-determined under the new conditions."( Effects of ketocyclazocine alone and in combination with naloxone on schedule-controlled responding in squirrel monkeys.
Dykstra, LA; Milar, KS, 1983
)
0.27
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Protein Targets (4)

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Mu-type opioid receptorHomo sapiens (human)IC50 (µMol)0.13000.00010.813310.0000AID410730
Kappa-type opioid receptorCavia porcellus (domestic guinea pig)Ki0.00100.00000.20186.4240AID410725
Mu-type opioid receptorCavia porcellus (domestic guinea pig)Ki0.00330.00000.27869.0000AID410723
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Activation Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Mu-type opioid receptorHomo sapiens (human)EC50 (µMol)0.02100.00000.32639.4000AID410728
Kappa-type opioid receptorHomo sapiens (human)EC50 (µMol)0.00330.00000.22448.9900AID410731
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (41)

Processvia Protein(s)Taxonomy
G protein-coupled receptor signaling pathway, coupled to cyclic nucleotide second messengerMu-type opioid receptorHomo sapiens (human)
adenylate cyclase-inhibiting G protein-coupled acetylcholine receptor signaling pathwayMu-type opioid receptorHomo sapiens (human)
phospholipase C-activating G protein-coupled receptor signaling pathwayMu-type opioid receptorHomo sapiens (human)
sensory perceptionMu-type opioid receptorHomo sapiens (human)
negative regulation of cell population proliferationMu-type opioid receptorHomo sapiens (human)
sensory perception of painMu-type opioid receptorHomo sapiens (human)
G protein-coupled opioid receptor signaling pathwayMu-type opioid receptorHomo sapiens (human)
behavioral response to ethanolMu-type opioid receptorHomo sapiens (human)
positive regulation of neurogenesisMu-type opioid receptorHomo sapiens (human)
negative regulation of Wnt protein secretionMu-type opioid receptorHomo sapiens (human)
positive regulation of ERK1 and ERK2 cascadeMu-type opioid receptorHomo sapiens (human)
calcium ion transmembrane transportMu-type opioid receptorHomo sapiens (human)
cellular response to morphineMu-type opioid receptorHomo sapiens (human)
regulation of cellular response to stressMu-type opioid receptorHomo sapiens (human)
regulation of NMDA receptor activityMu-type opioid receptorHomo sapiens (human)
neuropeptide signaling pathwayMu-type opioid receptorHomo sapiens (human)
immune responseKappa-type opioid receptorHomo sapiens (human)
adenylate cyclase-inhibiting G protein-coupled receptor signaling pathwayKappa-type opioid receptorHomo sapiens (human)
phospholipase C-activating G protein-coupled receptor signaling pathwayKappa-type opioid receptorHomo sapiens (human)
chemical synaptic transmissionKappa-type opioid receptorHomo sapiens (human)
sensory perceptionKappa-type opioid receptorHomo sapiens (human)
locomotory behaviorKappa-type opioid receptorHomo sapiens (human)
sensory perception of painKappa-type opioid receptorHomo sapiens (human)
adenylate cyclase-inhibiting opioid receptor signaling pathwayKappa-type opioid receptorHomo sapiens (human)
response to insulinKappa-type opioid receptorHomo sapiens (human)
positive regulation of dopamine secretionKappa-type opioid receptorHomo sapiens (human)
negative regulation of luteinizing hormone secretionKappa-type opioid receptorHomo sapiens (human)
response to nicotineKappa-type opioid receptorHomo sapiens (human)
G protein-coupled opioid receptor signaling pathwayKappa-type opioid receptorHomo sapiens (human)
maternal behaviorKappa-type opioid receptorHomo sapiens (human)
eating behaviorKappa-type opioid receptorHomo sapiens (human)
response to estrogenKappa-type opioid receptorHomo sapiens (human)
estrous cycleKappa-type opioid receptorHomo sapiens (human)
response to ethanolKappa-type opioid receptorHomo sapiens (human)
regulation of saliva secretionKappa-type opioid receptorHomo sapiens (human)
behavioral response to cocaineKappa-type opioid receptorHomo sapiens (human)
sensory perception of temperature stimulusKappa-type opioid receptorHomo sapiens (human)
defense response to virusKappa-type opioid receptorHomo sapiens (human)
cellular response to lipopolysaccharideKappa-type opioid receptorHomo sapiens (human)
cellular response to glucose stimulusKappa-type opioid receptorHomo sapiens (human)
positive regulation of p38MAPK cascadeKappa-type opioid receptorHomo sapiens (human)
positive regulation of potassium ion transmembrane transportKappa-type opioid receptorHomo sapiens (human)
response to acrylamideKappa-type opioid receptorHomo sapiens (human)
positive regulation of eating behaviorKappa-type opioid receptorHomo sapiens (human)
conditioned place preferenceKappa-type opioid receptorHomo sapiens (human)
neuropeptide signaling pathwayKappa-type opioid receptorHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (11)

Processvia Protein(s)Taxonomy
G-protein alpha-subunit bindingMu-type opioid receptorHomo sapiens (human)
G protein-coupled receptor activityMu-type opioid receptorHomo sapiens (human)
beta-endorphin receptor activityMu-type opioid receptorHomo sapiens (human)
voltage-gated calcium channel activityMu-type opioid receptorHomo sapiens (human)
protein bindingMu-type opioid receptorHomo sapiens (human)
morphine receptor activityMu-type opioid receptorHomo sapiens (human)
G-protein beta-subunit bindingMu-type opioid receptorHomo sapiens (human)
neuropeptide bindingMu-type opioid receptorHomo sapiens (human)
G protein-coupled opioid receptor activityKappa-type opioid receptorHomo sapiens (human)
protein bindingKappa-type opioid receptorHomo sapiens (human)
receptor serine/threonine kinase bindingKappa-type opioid receptorHomo sapiens (human)
dynorphin receptor activityKappa-type opioid receptorHomo sapiens (human)
neuropeptide bindingKappa-type opioid receptorHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (19)

Processvia Protein(s)Taxonomy
endosomeMu-type opioid receptorHomo sapiens (human)
endoplasmic reticulumMu-type opioid receptorHomo sapiens (human)
Golgi apparatusMu-type opioid receptorHomo sapiens (human)
plasma membraneMu-type opioid receptorHomo sapiens (human)
axonMu-type opioid receptorHomo sapiens (human)
dendriteMu-type opioid receptorHomo sapiens (human)
perikaryonMu-type opioid receptorHomo sapiens (human)
synapseMu-type opioid receptorHomo sapiens (human)
plasma membraneMu-type opioid receptorHomo sapiens (human)
neuron projectionMu-type opioid receptorHomo sapiens (human)
nucleoplasmKappa-type opioid receptorHomo sapiens (human)
mitochondrionKappa-type opioid receptorHomo sapiens (human)
cytosolKappa-type opioid receptorHomo sapiens (human)
plasma membraneKappa-type opioid receptorHomo sapiens (human)
membraneKappa-type opioid receptorHomo sapiens (human)
sarcoplasmic reticulumKappa-type opioid receptorHomo sapiens (human)
T-tubuleKappa-type opioid receptorHomo sapiens (human)
dendriteKappa-type opioid receptorHomo sapiens (human)
synaptic vesicle membraneKappa-type opioid receptorHomo sapiens (human)
presynaptic membraneKappa-type opioid receptorHomo sapiens (human)
perikaryonKappa-type opioid receptorHomo sapiens (human)
axon terminusKappa-type opioid receptorHomo sapiens (human)
postsynaptic membraneKappa-type opioid receptorHomo sapiens (human)
plasma membraneKappa-type opioid receptorHomo sapiens (human)
neuron projectionKappa-type opioid receptorHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (12)

Assay IDTitleYearJournalArticle
AID410727Ratio of Ki for delta opioid receptor to Ki for kappa opioid receptor in guinea pig brain2009Bioorganic & medicinal chemistry letters, Jan-01, Volume: 19, Issue:1
Syntheses and opioid receptor binding properties of carboxamido-substituted opioids.
AID410733Activity at human cloned kappa opioid receptor expressed in CHO cells assessed as inhibition of U50488-induced [35S]GTPgammaS binding2009Bioorganic & medicinal chemistry letters, Jan-01, Volume: 19, Issue:1
Syntheses and opioid receptor binding properties of carboxamido-substituted opioids.
AID410732Activity at human cloned kappa opioid receptor expressed in CHO cells by [35S]GTPgammaS binding assay relative to basal GTPgammaS binding2009Bioorganic & medicinal chemistry letters, Jan-01, Volume: 19, Issue:1
Syntheses and opioid receptor binding properties of carboxamido-substituted opioids.
AID410730Activity at human cloned mu opioid receptor expressed in CHO cells assessed as inhibition of DAMGO-induced [35S]GTPgammaS binding2009Bioorganic & medicinal chemistry letters, Jan-01, Volume: 19, Issue:1
Syntheses and opioid receptor binding properties of carboxamido-substituted opioids.
AID410728Activity at human cloned mu opioid receptor expressed in CHO cells by [35S]GTPgammaS binding assay2009Bioorganic & medicinal chemistry letters, Jan-01, Volume: 19, Issue:1
Syntheses and opioid receptor binding properties of carboxamido-substituted opioids.
AID410729Activity at human cloned mu opioid receptor expressed in CHO cells by [35S]GTPgammaS binding assay relative to basal GTPgammaS binding2009Bioorganic & medicinal chemistry letters, Jan-01, Volume: 19, Issue:1
Syntheses and opioid receptor binding properties of carboxamido-substituted opioids.
AID410725Displacement of [3H]U69593 form kappa opioid receptor in guinea pig brain2009Bioorganic & medicinal chemistry letters, Jan-01, Volume: 19, Issue:1
Syntheses and opioid receptor binding properties of carboxamido-substituted opioids.
AID410724Displacement of [3H]Naltrindole form delta opioid receptor in guinea pig brain2009Bioorganic & medicinal chemistry letters, Jan-01, Volume: 19, Issue:1
Syntheses and opioid receptor binding properties of carboxamido-substituted opioids.
AID227718Binding energy by using the equation deltaG obsd = -RT ln KD1984Journal of medicinal chemistry, Dec, Volume: 27, Issue:12
Functional group contributions to drug-receptor interactions.
AID410731Activity at human cloned kappa opioid receptor expressed in CHO cells by [35S]GTPgammaS binding assay2009Bioorganic & medicinal chemistry letters, Jan-01, Volume: 19, Issue:1
Syntheses and opioid receptor binding properties of carboxamido-substituted opioids.
AID410723Displacement of [3H]DAMGO form mu opioid receptor in guinea pig brain2009Bioorganic & medicinal chemistry letters, Jan-01, Volume: 19, Issue:1
Syntheses and opioid receptor binding properties of carboxamido-substituted opioids.
AID410726Ratio of Ki for mu opioid receptor to Ki for kappa opioid receptor in guinea pig brain2009Bioorganic & medicinal chemistry letters, Jan-01, Volume: 19, Issue:1
Syntheses and opioid receptor binding properties of carboxamido-substituted opioids.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (106)

TimeframeStudies, This Drug (%)All Drugs %
pre-199085 (80.19)18.7374
1990's17 (16.04)18.2507
2000's3 (2.83)29.6817
2010's1 (0.94)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 18.56

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index18.56 (24.57)
Research Supply Index4.72 (2.92)
Research Growth Index3.98 (4.65)
Search Engine Demand Index18.60 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (18.56)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials3 (2.78%)5.53%
Reviews3 (2.78%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other102 (94.44%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]